- Shares of nan cap Advaxis (OTC:ADXS +12.9%) jump on a 6x surge in volume in response to its announcement of a clinical trial collaboration with Merck (MRK +1%) that will evaluate the combination of Advaxis' Lm-LLO cancer immunotherapy, ADXS-PSA with Merck's investigational anti PD-1 Ab, pembrolizumab.
- The Phase 1/2 trial will assess the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer.
- The Phase 1 segment is designed to establish a dose regimen for ADXS-PSA alone. The Phase 2 segment will assess the safety and efficacy of the combination. The trial will commence in early 2015. The results will determine if further development is warranted.
Advaxis teams up with Merck in prostate cancer
Recommended For You
About ADXS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ADXS | - | - |
Ayala Pharmaceuticals, Inc. |